Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer

NCT03323658 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03323658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03323658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
June 15, 2018
Completion date
March 25, 2022
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast atypical ductal hyperplasia, breast atypical lobular hyperplasia, breast ductal carcinoma in situ, breast lobular carcinoma in situ, invasive breast carcinoma